PBM OptumRx Resolves DEA’s Allegations of Decade-Old CSA Violations Through $20 Million Settlement

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson Controlled Substances Module, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

PBM OptumRx Resolves DEA’s Allegations of Decade-Old CSA Violations Through $20 Million Settlement

Dennis Tosh

July 8, 2024 at 16:09:23 ET

Resolving a DEA investigation into allegedly illegal prescription practices that occurred a decade ago, the pharmacy benefit manager (PBM) company OptumRx Inc. has agreed to pay $20 million to settle allegations that for two years it improperly filled prescriptions for opioids in violation of the Controlled Substances Act (CSA). According to the Department of Justice (DOJ), between... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

PBM OptumRx Resolves DEA’s Allegations of Decade-Old CSA Violations Through $20 Million Settlement

My Research Folders

THOMPSON CONTROLLED SUBSTANCES

COMPLIANCE EXPERT

DEA RESOURCES

HELP

CONTACT